Abstract 2135P
Background
G8 and GA assessments to screen for frailty and facilitate appropriate interventions have been recommended by the International Society for Geriatric Oncology in older adults with cancer. The main objective of this study is to evaluate the impact of G8 and GA-based interventions on the QoL of older Asian adults with cancer.
Methods
This is a prospective study of cancer patients aged ≥70 treated at the National University Cancer Institute, Singapore. The G8, CGA, and EORTC QLQ 30 questionnaires were administered at study entry. Targeted interventions were offered by the multi-disciplinary geriatric oncology (GO) service. After three months, a follow-up EORTC QLQ 30 was repeated for those who required geriatric interventions. Primary outcome measure was comparison of pre/post- EORTC QLQ 30 scores.
Results
N=230 patients were accrued. Median age was 74 (range:70-90). Majority were male (56%), diagnosed with gastrointestinal cancers (35%) and receiving palliative intent treatment (60%). Based on GA, 11% were classified as frail, 58% as pre-frail and 31% as fit. 79% had G8 scores ≤14. Pre-frail, frail and those with G8 ≤14 had lower baseline EORTC QOL function scores and higher EORTC QOL symptom scores (p<0.05). They also had significantly shorter overall survival (OS) compared to fit or with patients G8>14. (HR=2.54 95% CI 1.46-4.43, p=0.001 for frail vs fit patients; HR=1.72 95% CI 1.18-2.53, p=0.005 for pre-frail vs fit patients; HR=1.51 95% CI 1.05-2.18, p=0.027 for G8 ≤14 vs >14). GO interventions were suggested for 144 patients with 104 patients completing a 2nd EORTC QOL questionnaire. These patients reported significant improvements in the EORTC emotional and social functioning domains (mean difference +4.6, p<0.001 and +12.3 p<0.001, respectively), a significant reduction in the EORTC symptom scale of pain, insomnia, constipation, and financial difficulties (mean difference -5.8 p=0.003, -8.3 p<0.001, -9.0 p<0.001, and -6 p=0.01), with no significant deterioration in other QOL domains.
Conclusions
Geriatric assessment-based targeted interventions delivered by a multidisciplinary GO service significantly improved multiple QOL domains in older Asian adults undergoing cancer treatment.
Clinical trial identification
DSRB Study Reference Number: 2017/00214.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Singapore Cancer Society.
Disclosure
C.E. Chee: Financial Interests, Institutional, Advisory Board: Merck, AstraZeneca, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2162P - Can artificial intelligence provide accurate and reliable answers to cancer patients' questions? Comparison of chatbots based on the ESMO Patient Guide about cancer pain
Presenter: Kadriye Bir Yucel
Session: Poster session 07
2163P - Supportive care in French community pharmacies: OncoPharma certification
Presenter: Jérôme Sicard
Session: Poster session 07
2164P - The impact of cancer patients’ face masks on oxygenation and Co2 retention during treatment
Presenter: Mert Sahin
Session: Poster session 07
2165P - A French overview of electronic patient-reported outcomes use in 2022
Presenter: Melina Hocine
Session: Poster session 07
2166P - Long-term consequences of SARS-CoV-2 infection in cancer patients
Presenter: Yana Debie
Session: Poster session 07
2167P - Are bone targeted agents (BTAs) still useful in times of immunotherapy? The SAKK 80/19 BTA study
Presenter: Michael Mark
Session: Poster session 07
2168P - At-home infusion of immunotherapy for patients with solid tumors: First results from a single-centre program
Presenter: Javier Marco Hernández
Session: Poster session 07
2169P - Immunotherapy-based treatment in elderly cancer patients: A real-world multicenter study
Presenter: Mengye He
Session: Poster session 07
2171P - Incidence of adverse events in patients treated with a combination of immune checkpoint blockers and chemotherapy: A real life cohort
Presenter: Layal Rached
Session: Poster session 07
2172P - Development and evaluation of the usefulness of an immune-related adverse events interview application
Presenter: AKIKO YANO
Session: Poster session 07